NCT07351786 Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy
| NCT ID | NCT07351786 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sara A Belal |
| Condition | Diabetes (DM) |
| Study Type | OBSERVATIONAL |
| Enrollment | 70 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 70 participants in total. It began in 2025-08-01 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to test the impact of new-generation anti-diabetic drugs, such as SGLT2 inhibitors and DPP-4 inhibitors, on the development of diabetic retinopathy (DR). The study hypothesizes that these drugs have protective effects in diabetic retinopathy by delaying its incidence compared to older agents (including metformin) only. Early intervention is critical, as treatment options for advanced stages of DR are limited in terms of their ability to restore impaired vision and their high associated costs. By focusing on delaying the occurrence of diabetic retinopathy, the investigators aim to reduce the burden of DR and improve the quality of life for diabetic patients.
Eligibility Criteria
Inclusion Criteria: * Diagnosed with Type 2 Diabetes for \>5 years * Using Diabetes medications (metformin, sulfonylureas, SGLT2 inhibitors, DPP-4 inhibitors) for a period of 2-3 years Exclusion Criteria: * Gestational Diabetes * Type 1 Diabetes * Severe non-proliferative diabetic retinopathy (NPDR) at baseline * Proliferative diabetic retinopathy (PDR) at baseline * Pregnant and breastfeeding women
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07351786 clinical trial?
This trial is open to participants of all sexes, aged 25 Years or older, studying Diabetes (DM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07351786 currently recruiting?
Yes, NCT07351786 is actively recruiting participants. Contact the research team at phar-sara.belal@alexu.edu.eg for enrollment information.
Where is the NCT07351786 trial being conducted?
This trial is being conducted at Alexandria, Egypt.
Who is sponsoring the NCT07351786 clinical trial?
NCT07351786 is sponsored by Sara A Belal. The trial plans to enroll 70 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.